PitchSend

Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 63 Stable insulin leadership position in Region AAMEO Region AAMEO insulin market by segment Region AAMEO modern and new-generation insulin volume market shares tMU 120 100 80 40 20 60 642 0 Aug 2013 - Device penetration - MI and NGI penetration Penetration CAGR volume¹: 7.5% CAGR value¹: 4.1% 100% 70% 60% 80% Fast-acting 50% 60% 40% Premix 30% 40% 20% 20% Long-acting 10% 0% 0% Aug 2018 Aug 2013 - Novo Nordisk - Sanofi Eli Lilly Other 1 CAGR for 5-year period. Note: IQVIA only covers the following 8 markets in AAMEO (retail data): Algeria, Egypt, India, New Zealand, Russia, Saudi Arabia, South Africa and Turkey, which together accounts for 82% of Novo Nordisk insulin sales in region AAMEO Source: IQVIA monthly MAT Aug, 2018 volume and value (DKK) figures AAMEO: Africa, Asia, the Middle-East and Oceania; MI: Modern insulin; NGI: New-generation insulin Source: IQVIA monthly MAT Aug, 2018 volume figures 56% 20% 14% 10% Aug 2018 novo nordisk

View entire presentation